← All news

FROM THE NEWS FEED

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-06 β€’ Psychedelic Invest

Article summary

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND…

Continue to the original publication for the complete article.